Aprepitant is Safe in Renal Failure Without Dose Adjustment
Aprepitant can be safely used at standard doses in patients with renal failure, including those with end-stage renal disease (ESRD) on hemodialysis, without any dose adjustment required. 1
FDA-Approved Dosing in Renal Impairment
The FDA drug label explicitly states: "No dosage adjustment is necessary for patients with any degree of renal impairment or for patients with ESRD undergoing hemodialysis." 1 This recommendation is based on pharmacokinetic studies demonstrating that aprepitant clearance is not significantly affected by renal dysfunction.
Pharmacokinetic Evidence
The definitive pharmacokinetic study evaluated aprepitant 240 mg in patients with ESRD requiring hemodialysis and severe renal insufficiency (creatinine clearance <30 mL/min) 2. Key findings include:
- In ESRD patients, total aprepitant AUC was 36% lower than controls, but the 90% confidence interval (0.52-0.78) fell within the predefined acceptable range of 0.5-2.0
- Most importantly, unbound aprepitant AUC (the pharmacologically active fraction) showed no clinically significant difference between ESRD patients and healthy controls
- Hemodialysis timing (initiated at 4 hours vs. 48 hours post-dose) had no clinically meaningful effect on aprepitant pharmacokinetics
- In severe renal insufficiency patients, the AUC ratio was 0.79 (90% CI: 0.56-1.10), demonstrating no statistically significant difference from controls
- Aprepitant was well tolerated in both groups
Clinical Implications
The lack of dose adjustment requirement is explained by aprepitant's metabolism: The drug undergoes extensive hepatic metabolism via CYP3A4, with minimal renal excretion 1. This metabolic pathway remains intact in renal failure, maintaining predictable drug exposure.
For dialysis patients specifically: Aprepitant is highly protein-bound (>99.9%), making dialytic removal negligible 1. The study confirmed that hemodialysis does not significantly remove aprepitant from the circulation 2.
Practical Prescribing
- Standard dosing applies: Use the same aprepitant regimen (typically 125 mg on day 1, then 80 mg on days 2-3 for chemotherapy-induced nausea) regardless of renal function
- No monitoring required: Unlike many medications in renal failure, aprepitant does not require dose titration, therapeutic drug monitoring, or timing adjustments around dialysis sessions
- Dialysis timing irrelevant: Administer aprepitant without regard to hemodialysis schedule
Important Caveat
While renal impairment requires no adjustment, hepatic impairment is different. Patients with severe hepatic impairment (Child-Pugh score >9) lack safety data and may warrant additional monitoring 1. However, mild-to-moderate hepatic impairment (Child-Pugh 5-9) requires no dose adjustment.
Bottom line: Aprepitant is one of the few medications that can be dosed identically in patients with normal renal function and those with ESRD on dialysis, making it a straightforward choice for antiemetic therapy in this population.